New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Scribe Therapeutics Inc. 10-Q filed Nov 12, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:22 PM ET · Document on sec.gov · Filing index

Read the filing on sec.gov

Nothing in this filing raised a red flag. The document itself is on sec.gov.